Additionally, this combination resulted in increased rates of pathologic complete response and enhanced infiltration of immune cells in operable NSCLC, and an examination of neoadjuvant chemotherapy, combined with ipilimumab in early-stage NSCLC, demonstrated notable immune stimulation, especially in CD4+ and CD8+ lymphocytes [246]. Here, CD4 is linked to non-small cell lung carcinoma.